You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Not Available
Identification
NameIproniazid
Accession NumberDB04818
TypeSmall Molecule
GroupsWithdrawn
DescriptionWithdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EuphozidNot Available
IprazidNot Available
IpronidA.F.I.
IproninNot Available
MarsilidGenopharm
RivivolZambeletti
Brand mixturesNot Available
SaltsNot Available
Categories
UNIID892HFI3XA
CAS number54-92-2
WeightAverage: 179.219
Monoisotopic: 179.105862053
Chemical FormulaC9H13N3O
InChI KeyNYMGNSNKLVNMIA-UHFFFAOYSA-N
InChI
InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13)
IUPAC Name
N'-(propan-2-yl)pyridine-4-carbohydrazide
SMILES
CC(C)NNC(=O)C1=CC=NC=C1
Pharmacology
IndicationFor the treatment of depression (originally intended to treat tuberculosis).
Structured Indications Not Available
PharmacodynamicsIproniazid is a monoamine oxidase inhibitor (MAOI) that was developed as the first anti-depressant.
Mechanism of action
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineIproniazid may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineIproniazid may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineIproniazid may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineIproniazid may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEIproniazid may increase the hypertensive activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcarboseIproniazid may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololIproniazid may increase the hypotensive activities of Acebutolol.Approved
AlbiglutideIproniazid may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Iproniazid.Approved, Illicit
AliskirenIproniazid may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Iproniazid.Approved, Investigational
AlogliptinIproniazid may increase the hypoglycemic activities of Alogliptin.Approved
AlprenololIproniazid may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Iproniazid.Approved
AmbrisentanIproniazid may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineIproniazid may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineIproniazid may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineIproniazid may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Amoxapine.Approved
AmphetamineIproniazid may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Iproniazid.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Arformoterol.Approved, Investigational
AtenololIproniazid may increase the hypotensive activities of Atenolol.Approved
AtomoxetineIproniazid may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineIproniazid may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Bambuterol.Approved
BenazeprilIproniazid may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideIproniazid may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinIproniazid may increase the hypertensive activities of Benmoxin.Withdrawn
BenzphetamineIproniazid may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilIproniazid may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Iproniazid.Approved
BetaxololIproniazid may increase the hypotensive activities of Betaxolol.Approved
BethanidineIproniazid may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Iproniazid is combined with Bezafibrate.Approved
BimatoprostIproniazid may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololIproniazid may increase the hypotensive activities of Bisoprolol.Approved
BosentanIproniazid may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumIproniazid may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Brimonidine.Approved
BrimonidineIproniazid may increase the hypotensive activities of Brimonidine.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Iproniazid.Approved, Investigational
BupranololIproniazid may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Iproniazid.Approved, Illicit, Investigational, Vet Approved
BupropionIproniazid may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Iproniazid.Approved, Investigational
CabergolineThe metabolism of Cabergoline can be decreased when combined with Iproniazid.Approved
CanagliflozinIproniazid may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanIproniazid may increase the hypotensive activities of Candesartan.Approved
CandoxatrilIproniazid may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilIproniazid may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Iproniazid.Approved, Investigational
CaroxazoneIproniazid may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololIproniazid may increase the hypotensive activities of Carteolol.Approved
CarvedilolIproniazid may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololIproniazid may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideIproniazid may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineIproniazid may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamideIproniazid may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneIproniazid may increase the hypotensive activities of Chlorthalidone.Approved
CilazaprilIproniazid may increase the hypotensive activities of Cilazapril.Approved
CirazolineIproniazid may increase the hypertensive activities of Cirazoline.Experimental
CitalopramIproniazid may increase the serotonergic activities of Citalopram.Approved
ClemastineIproniazid may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Clenbuterol.Approved, Vet Approved
ClomipramineIproniazid may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidineIproniazid may increase the hypotensive activities of Clonidine.Approved
CryptenamineIproniazid may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Iproniazid.Approved
CyclothiazideIproniazid may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineIproniazid may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinIproniazid may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineIproniazid may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinIproniazid may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineIproniazid may increase the hypotensive activities of Deserpidine.Approved
DesipramineIproniazid may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxineIproniazid may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidateIproniazid may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineIproniazid may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanIproniazid may increase the serotonergic activities of Dextromethorphan.Approved
DiazoxideIproniazid may increase the hypotensive activities of Diazoxide.Approved
DiethylpropionIproniazid may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineIproniazid may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Iproniazid.Approved
DiltiazemIproniazid may increase the hypotensive activities of Diltiazem.Approved
DipivefrinThe risk or severity of adverse effects can be increased when Iproniazid is combined with Dipivefrin.Approved
DisopyramideIproniazid may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideIproniazid may increase the hypotensive activities of Dorzolamide.Approved
DosulepinIproniazid may increase the serotonergic activities of Dosulepin.Approved
DoxapramIproniazid may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinIproniazid may increase the hypotensive activities of Doxazosin.Approved
DoxepinIproniazid may increase the serotonergic activities of Doxepin.Approved
DoxylamineIproniazid may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DroxidopaThe risk or severity of adverse effects can be increased when Iproniazid is combined with Droxidopa.Approved, Investigational
DulaglutideIproniazid may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineIproniazid may increase the serotonergic activities of Duloxetine.Approved
EfonidipineIproniazid may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Iproniazid.Approved, Investigational
EmpagliflozinIproniazid may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilIproniazid may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatIproniazid may increase the hypotensive activities of Enalaprilat.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Iproniazid.Approved, Investigational
EphedraThe risk or severity of adverse effects can be increased when Iproniazid is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineIproniazid may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolIproniazid may increase the hypotensive activities of Epoprostenol.Approved
EprosartanIproniazid may increase the hypotensive activities of Eprosartan.Approved
ErgotamineIproniazid may increase the hypertensive activities of Ergotamine.Approved
EscitalopramIproniazid may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineIproniazid may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Iproniazid.Approved
EtoperidoneIproniazid may increase the serotonergic activities of Etoperidone.Approved
ExenatideIproniazid may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineIproniazid may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamIproniazid may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Fenoterol.Approved
FentanylFentanyl may increase the serotonergic activities of Iproniazid.Approved, Illicit, Investigational, Vet Approved
FluoxetineIproniazid may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxamineIproniazid may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Formoterol.Approved, Investigational
FosinoprilIproniazid may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Iproniazid.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Iproniazid.Approved, Vet Approved
GliclazideIproniazid may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideIproniazid may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideIproniazid may increase the hypoglycemic activities of Glipizide.Approved
GlyburideIproniazid may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzIproniazid may increase the hypotensive activities of Guanabenz.Approved
GuanadrelIproniazid may increase the hypotensive activities of Guanadrel.Approved
GuanethidineIproniazid may increase the hypotensive activities of Guanethidine.Approved
GuanfacineIproniazid may increase the hypotensive activities of Guanfacine.Approved, Investigational
HexamethoniumIproniazid may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineIproniazid may increase the hypertensive activities of Hydracarbazine.Approved
HydralazineIproniazid may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideIproniazid may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideIproniazid may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideIproniazid may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.Approved
ImidaprilIproniazid may increase the hypotensive activities of Imidapril.Investigational
ImipramineIproniazid may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Indacaterol.Approved
IndalpineIproniazid may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideIproniazid may increase the hypotensive activities of Indapamide.Approved
IndenololIproniazid may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminIproniazid may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartIproniazid may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirIproniazid may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineIproniazid may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineIproniazid may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanIproniazid may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproIproniazid may increase the hypoglycemic activities of Insulin Lispro.Approved
IproclozideIproniazid may increase the hypertensive activities of Iproclozide.Withdrawn
IrbesartanIproniazid may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Iproniazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Isoprenaline.Approved
IsradipineIproniazid may increase the hypotensive activities of Isradipine.Approved
KetanserinIproniazid may increase the hypotensive activities of Ketanserin.Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Iproniazid.Approved, Nutraceutical
LabetalolIproniazid may increase the hypotensive activities of Labetalol.Approved
LacidipineIproniazid may increase the hypotensive activities of Lacidipine.Approved
LanreotideIproniazid may increase the hypoglycemic activities of Lanreotide.Approved
LatanoprostIproniazid may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineIproniazid may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Iproniazid.Approved
LevomilnacipranIproniazid may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinIproniazid may increase the hypertensive activities of Levonordefrin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Linezolid.Approved, Investigational
LiraglutideIproniazid may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineIproniazid may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilIproniazid may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Iproniazid.Approved
LithiumThe risk or severity of adverse effects can be increased when Iproniazid is combined with Lithium.Approved
LofexidineIproniazid may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanIproniazid may increase the hypotensive activities of Losartan.Approved
Lu AA21004The metabolism of Lu AA21004 can be decreased when combined with Iproniazid.Investigational
MacitentanIproniazid may increase the hypotensive activities of Macitentan.Approved
ManidipineIproniazid may increase the hypotensive activities of Manidipine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Iproniazid.Approved
MebanazineIproniazid may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineIproniazid may increase the hypotensive activities of Mecamylamine.Approved
MecaserminIproniazid may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedroneIproniazid may increase the hypertensive activities of Mephedrone.Investigational
MephentermineIproniazid may increase the hypertensive activities of Mephentermine.Approved
MequitazineIproniazid may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolIproniazid may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminIproniazid may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Methadone.Approved
MethamphetamineIproniazid may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoxamineIproniazid may increase the hypertensive activities of Methoxamine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Iproniazid is combined with Methyldopa.Approved
Methylene blueIproniazid may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateIproniazid may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetipranololIproniazid may increase the hypotensive activities of Metipranolol.Approved
MetolazoneIproniazid may increase the hypotensive activities of Metolazone.Approved
MetoprololIproniazid may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineIproniazid may increase the hypotensive activities of Metyrosine.Approved
MianserinIproniazid may increase the neurotoxic activities of Mianserin.Approved
MibefradilIproniazid may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineIproniazid may increase the hypertensive activities of Midodrine.Approved
MifepristoneIproniazid may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolIproniazid may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranIproniazid may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Iproniazid.Approved
MinoxidilIproniazid may increase the hypotensive activities of Minoxidil.Approved
MirtazapineIproniazid may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAIproniazid may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Iproniazid is combined with Moclobemide.Approved
MoexiprilIproniazid may increase the hypotensive activities of Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Morphine.Approved, Investigational
MoxonidineIproniazid may increase the hypotensive activities of Moxonidine.Approved
NadololIproniazid may increase the hypotensive activities of Nadolol.Approved
NaftopidilIproniazid may increase the hypotensive activities of Naftopidil.Investigational
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Iproniazid.Approved, Investigational
NateglinideIproniazid may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololIproniazid may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneIproniazid may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideIproniazid may increase the hypertensive activities of Nialamide.Withdrawn
NicardipineIproniazid may increase the hypotensive activities of Nicardipine.Approved
NicorandilIproniazid may increase the hypotensive activities of Nicorandil.Approved
NiguldipineIproniazid may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineIproniazid may increase the hypotensive activities of Nilvadipine.Approved
NimodipineIproniazid may increase the hypotensive activities of Nimodipine.Approved
NisoldipineIproniazid may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineIproniazid may increase the hypotensive activities of Nitrendipine.Approved
NitroprussideIproniazid may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineIproniazid may increase the hypertensive activities of Norepinephrine.Approved
NortriptylineIproniazid may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinIproniazid may increase the hypertensive activities of Octamoxin.Withdrawn
OctreotideIproniazid may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Olanzapine.Approved, Investigational
OlmesartanIproniazid may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Olodaterol.Approved
OmapatrilatIproniazid may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolIproniazid may increase the serotonergic activities of Opipramol.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Orciprenaline.Approved
OxprenololIproniazid may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iproniazid.Approved, Investigational, Vet Approved
PargylinePargyline may increase the hypertensive activities of Iproniazid.Approved
ParoxetineIproniazid may increase the serotonergic activities of Paroxetine.Approved, Investigational
PasireotideIproniazid may increase the hypoglycemic activities of Pasireotide.Approved
PenbutololIproniazid may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineIproniazid may increase the hypoglycemic activities of Pentamidine.Approved
PentoliniumIproniazid may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Iproniazid.Approved, Vet Approved, Withdrawn
PerindoprilIproniazid may increase the hypotensive activities of Perindopril.Approved
PethidineIproniazid may increase the serotonergic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Iproniazid.Approved
PheniprazineIproniazid may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoxybenzamineIproniazid may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineIproniazid may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineIproniazid may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineIproniazid may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineIproniazid may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Iproniazid.Approved, Illicit
PinacidilIproniazid may increase the hypotensive activities of Pinacidil.Withdrawn
PindololIproniazid may increase the hypotensive activities of Pindolol.Approved
PioglitazoneIproniazid may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Pirbuterol.Approved
PirlindoleIproniazid may increase the hypertensive activities of Pirlindole.Approved
PivhydrazineIproniazid may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenIproniazid may increase the anticholinergic activities of Pizotifen.Approved
PolythiazideIproniazid may increase the hypotensive activities of Polythiazide.Approved
PramlintideIproniazid may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinIproniazid may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Procaterol.Approved
PropranololIproniazid may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineIproniazid may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Iproniazid.Investigational
PseudoephedrineIproniazid may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilIproniazid may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineIproniazid may increase the hypoglycemic activities of Quinine.Approved
RamiprilIproniazid may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Iproniazid.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Iproniazid.Approved
RemikirenIproniazid may increase the hypotensive activities of Remikiren.Approved
RepaglinideIproniazid may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineIproniazid may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Reserpine.Approved
RilmenidineIproniazid may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatIproniazid may increase the hypotensive activities of Riociguat.Approved
RitobegronIproniazid may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Ritodrine.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Iproniazid.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Iproniazid.Approved, Investigational
RosiglitazoneIproniazid may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineIproniazid may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Salmeterol.Approved
SaprisartanIproniazid may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinIproniazid may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Iproniazid.Approved, Investigational, Vet Approved
SelexipagIproniazid may increase the hypotensive activities of Selexipag.Approved
SertralineIproniazid may increase the serotonergic activities of Sertraline.Approved
SitagliptinIproniazid may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanIproniazid may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilIproniazid may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Iproniazid.Approved, Investigational
SulfadiazineIproniazid may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleIproniazid may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleIproniazid may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Iproniazid.Approved, Investigational
SunitinibIproniazid may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Iproniazid.Approved
TelmisartanIproniazid may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilIproniazid may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Terbutaline.Approved
TerlipressinIproniazid may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Iproniazid.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Iproniazid.Approved
TetryzolineIproniazid may increase the hypertensive activities of Tetryzoline.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Iproniazid.Approved
TiboloneIproniazid may increase the hypotensive activities of Tibolone.Approved
TicrynafenIproniazid may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololIproniazid may increase the hypotensive activities of Timolol.Approved
TolazamideIproniazid may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineIproniazid may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideIproniazid may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iproniazid.Approved, Withdrawn
ToloxatoneIproniazid may increase the hypertensive activities of Toloxatone.Approved
TorasemideIproniazid may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Iproniazid.Approved, Investigational
TrandolaprilIproniazid may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Iproniazid.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Iproniazid.Approved
TravoprostIproniazid may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Trazodone.Approved, Investigational
TreprostinilIproniazid may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideIproniazid may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinIproniazid may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanIproniazid may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineIproniazid may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneIproniazid may increase the hypotensive activities of Unoprostone.Approved
ValsartanIproniazid may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineIproniazid may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Iproniazid.Approved
VinpocetineIproniazid may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Iproniazid.Approved
XylometazolineIproniazid may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineIproniazid may increase the serotonergic activities of Zimelidine.Withdrawn
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Iproniazid.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

U.S. Patent 2,685,585.

General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9929
Blood Brain Barrier+0.9799
Caco-2 permeable+0.6657
P-glycoprotein substrateNon-substrate0.7484
P-glycoprotein inhibitor INon-inhibitor0.9191
P-glycoprotein inhibitor IINon-inhibitor0.9932
Renal organic cation transporterNon-inhibitor0.9166
CYP450 2C9 substrateNon-substrate0.8608
CYP450 2D6 substrateNon-substrate0.873
CYP450 3A4 substrateNon-substrate0.614
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9316
CYP450 2D6 inhibitorNon-inhibitor0.9522
CYP450 2C19 inhibitorNon-inhibitor0.9293
CYP450 3A4 inhibitorNon-inhibitor0.7165
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9221
Ames testNon AMES toxic0.5653
CarcinogenicityNon-carcinogens0.7081
BiodegradationNot ready biodegradable0.9893
Rat acute toxicity2.6600 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9869
hERG inhibition (predictor II)Non-inhibitor0.943
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point161-161.5U.S. Patent 2,685,585.
logP0.37HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.674 mg/mLALOGPS
logP0.02ALOGPS
logP0.31ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)13.66ChemAxon
pKa (Strongest Basic)3.82ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area54.02 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity60.96 m3·mol-1ChemAxon
Polarizability19.19 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinecarboxylic acids and derivatives. These are compounds containing a pyridine ring bearing a carboxylic acid group or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPyridinecarboxylic acids and derivatives
Direct ParentPyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Pyridine carboxylic acid or derivatives
  • Heteroaromatic compound
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
Comments
comments powered by Disqus
Drug created on September 11, 2007 14:12 / Updated on August 17, 2016 12:24